Buoniello v. Ethicon Women's Health and Urology

CourtDistrict Court, E.D. New York
DecidedSeptember 29, 2020
Docket2:19-cv-04021
StatusUnknown

This text of Buoniello v. Ethicon Women's Health and Urology (Buoniello v. Ethicon Women's Health and Urology) is published on Counsel Stack Legal Research, covering District Court, E.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Buoniello v. Ethicon Women's Health and Urology, (E.D.N.Y. 2020).

Opinion

UNITED STATES DISTRICT COURT EASTERN DISTRICT OF NEW YORK -------------------------------------------------------X THERESA BUONIELLO,

Plaintiff, MEMORANDUM AND ORDER 2:19-cv-4021 (DRH)(ARL) - against -

ETHICON WOMEN’S HEALTH AND UROLOGY, a division of ETHICON, INC.; GYNECARE, a division of ETHICON, INC.; ETHICON, INC.; and JOHNSON & JOHNSON;

Defendants. -------------------------------------------------------X

APPEARANCES

For Plaintiff:

Martin Baughman, PLLC 3710 Rawlins Street, Suite 1230 Dallas, Texas 75219 By: Laura J. Baughman, Esq.

For Defendant:

Riker Danzig Scherer Hyland & Perretti LLP One Speedwell Avenue Morristown, New Jersey 07962 By: Kelly S. Crawford, Esq.

HURLEY, Senior District Judge:

INTRODUCTION

Plaintiff Theresa Buoniello (“Plaintiff” or “Buoniello”) brought this action against Defendants Ethicon Women’s Health and Urology, Gynecare, Ethicon, Inc., and Johnson & Johnson (collectively, “Defendants”), asserting claims for strict liability, negligence, fraud, fraudulent concealment, constructive fraud, negligent misrepresentation, negligent infliction of emotional distress, breach of express and implied warranty, violation of the New York Consumer Protection Act, gross negligence, unjust enrichment, punitive damages, and “discovery rule and tolling”. Presently before the Court is Defendants’ motion for partial dismissal pursuant to Fed. R. Civ. P (“Rule”) 12(b)(6) for failure to state a claim. For the reasons discussed below,

Defendants’ motion to dismiss is granted in part and denied in part. BACKGROUND The following relevant facts come from the Complaint (“Compl.”) and are assumed true for purposes of this motion. Defendants manufacture, market, and sell a variety of pelvic mesh products, including Prolene Mesh, Gynemesh, Prolift, Prosima, Prolift+M, and TVT (collectively, the “Pelvic Mesh Products”) to treat medical conditions in the female pelvis. (Compl. [ECF No. 1] ¶¶ 8, 14.) Defendants marketed the Pelvic Mesh Products “to the medical community, medical device manufacturers, and patients and consumers as safe, effective, and reliable medical devices that could be implanted by safe and effective, minimally invasive surgical techniques for the

treatment of medical conditions.” (Id. ¶ 19.) Plaintiff alleges, upon information and belief, that Defendants have misled the FDA, the medical community, patients, and the public at large about these products. (Id. ¶ 22.) In April of 2010, Plaintiff’s surgeon performed a surgical procedure and implanted Plaintiff with two of Defendants’ Pelvic Mesh Products, the Gynecare TVT-Obturator and the Prisma Anterior Pelvic Floor Repair System. (Id. ¶ 16.) These products were implanted to treat Plaintiff’s pelvic floor prolapse and/or stress urinary incontinence. (Id. ¶ 17.) Plaintiff alleges that, as a result of having the Pelvic Mesh Products implanted in her, she “has sustained permanent injuries, has required corrective surgery, will likely need additional corrective surgery, and has experienced and will continue to experience significant mental anguish and physical pain and suffering as well as financial and economic damages, including the cost of medical services and other related expenses.” (Id. ¶ 18.) DISCUSSION

I. The Parties’ Arguments Plaintiff brings fifteen causes of action against Defendants: (1) strict liability based on defective manufacture and design; (2) strict liability based on failure to warn; (3) negligence; (4) common law fraud; (5) fraudulent concealment; (6) constructive fraud; (7) negligent misrepresentation; (8) negligent infliction of emotional distress; (9) breach of express warranty; (10) breach of implied warranty; (11) violation of New York Consumer Protection Act; (12) gross negligence; (13) unjust enrichment; (14) punitive damages; and (15) discovery rule and tolling. (Compl. ¶¶ 35–184.) Defendants argue that many of Plaintiff’s claims are duplicative and should therefore be dismissed. In particular, Defendants contend that Plaintiff’s claims for negligence, negligent

misrepresentation, negligent infliction of emotional distress, and gross negligence are duplicative of the strict liability claims; that Plaintiff’s claims for fraud, fraudulent concealment, constructive fraud, negligent misrepresentation, breach of warranty, and consumer fraud are duplicative of the failure to warn claim; and that Plaintiff’s unjust enrichment claim is duplicative of the failure to warn claim. Defendants also argue that the learned intermediary doctrine serves as a bar to those claims sounding in fraud. Additionally, Defendants argue that Plaintiff’s claim for negligent infliction of emotional distress is not cognizable under New York law and that Plaintiff’s breach of warranty claims are time barred. Defendants also contend that New York law applies to Plaintiff’s substantive claims.1 (Defs.’ Mem. in Supp. [ECF No. 14-1].) Plaintiff agrees that New York law applies to her claims and does not oppose dismissal of the breach of warranty claims. Accordingly, those claims are dismissed. Plaintiff argues that she

is allowed to present alternative theories of liability and that, as to the claims sounding in fraud, the learned intermediary doctrine does not apply because she alleges a failure to adequately warn her health care professionals. She also argues that she has stated a cognizable claim for negligent infliction of emotional distress. (Pl.’s Mem. in Opp. [ECF No. 14-3].) II. Legal Standard In deciding a motion to dismiss under Rule 12(b)(6), a court should “draw all reasonable inferences in Plaintiff[’s] favor, assume all well-pleaded factual allegations to be true, and determine whether they plausibly give rise to an entitlement to relief.” Faber v. Metro. Life Ins. Co., 648 F.3d 98, 104 (2d Cir. 2011) (internal quotation marks omitted). The plausibility standard is guided by two principles. Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009) (citing Bell Atl.

Corp. v. Twombly, 550 U.S. 544 (2007)); accord Harris v. Mills, 572 F.3d 66, 71–72 (2d Cir. 2009). First, the principle that a court must accept all allegations as true is inapplicable to legal conclusions. Thus, “threadbare recitals of the elements of a cause of action supported by mere conclusory statements, do not suffice.” Iqbal, 556 U.S. at 678. Although “legal conclusions can provide the framework of a complaint, they must be supported by factual allegations.” Id. at 679. A plaintiff must provide facts sufficient to allow each named defendant to have a fair

1 Defendants contend, in a footnote, that Defendant Johnson & Johnson “is improperly named as Defendant because it does not develop, design, manufacture, market, or sell any products or services to the public.” (Defs. Mem. in Supp. at 1 n.1.) Since no motion has been filed to dismiss Johnson & Johnson, the Court does not address the issue. understanding of what the plaintiff is complaining about and to know whether there is a legal basis for recovery. See Twombly, 550 U.S. at 555. Second, only complaints that state a “plausible claim for relief” can survive a motion to dismiss. Iqbal, 556 U.S. at 679. “A claim has facial plausibility when the plaintiff pleads factual

content that allows the court to draw the reasonable inference that the defendant is liable for the misconduct alleged. The plausibility standard is not akin to a ‘probability requirement,’ but asks for more than a sheer possibility that defendant acted unlawfully.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Faber v. Metropolitan Life Insurance
648 F.3d 98 (Second Circuit, 2011)
In Re Elevator Antitrust Litigation
502 F.3d 47 (Second Circuit, 2007)
Harris v. Mills
572 F.3d 66 (Second Circuit, 2009)
Martin v. Hacker
628 N.E.2d 1308 (New York Court of Appeals, 1993)
Lee v. McCue
410 F. Supp. 2d 221 (S.D. New York, 2006)
Corsello v. Verizon New York, Inc.
967 N.E.2d 1177 (New York Court of Appeals, 2012)
Mandarin Trading Ltd. v. Wildenstein
944 N.E.2d 1104 (New York Court of Appeals, 2011)
Murphy v. American Home Products Corp.
448 N.E.2d 86 (New York Court of Appeals, 1983)
Lancaster Silo & Block Co. v. Northern Propane Gas Co.
75 A.D.2d 55 (Appellate Division of the Supreme Court of New York, 1980)
Wolkstein v. Morgenstern
275 A.D.2d 635 (Appellate Division of the Supreme Court of New York, 2000)
Cuoco v. Moritsugu
222 F.3d 99 (Second Circuit, 2000)
Greene v. Gerber Products Co.
262 F. Supp. 3d 38 (E.D. New York, 2017)
Anghel v. Sebelius
912 F. Supp. 2d 4 (E.D. New York, 2012)

Cite This Page — Counsel Stack

Bluebook (online)
Buoniello v. Ethicon Women's Health and Urology, Counsel Stack Legal Research, https://law.counselstack.com/opinion/buoniello-v-ethicon-womens-health-and-urology-nyed-2020.